Skip to content
HowShorted

RHYTHM PHARMACEUTICALS, INC. short interest in 2020

In 2020, RHYTHM PHARMACEUTICALS, INC.'s disclosed short interest ran from 4.85% of shares outstanding on 15 Jan 2020 to 6.24% on 31 Dec 2020, a change of +1.39 percentage points. The year's high was 6.24% on 31 Dec 2020 and its low 3.26% on 30 Apr 2020, averaging 4.33% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.74 days on 31 Jul 2020. Full history: RHYTHM PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RHYTHM PHARMACEUTICALS, INC. in 2020

2020 in figures

Start of year
4.85% (15 Jan 2020)
End of year
6.24% (31 Dec 2020)
Change
+1.39 pp
High
6.24% (31 Dec 2020)
Low
3.26% (30 Apr 2020)
Average
4.33%
Highest days to cover
14.74 (31 Jul 2020)
SEC filings marked
7

Every report in 2020

RHYTHM PHARMACEUTICALS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20204.85%10.83
31 Jan 20204.50%8.50
14 Feb 20203.93%12.51
28 Feb 20205.26%11.56
13 Mar 20203.63%6.6610-K filed, results (8-K)
31 Mar 20204.47%6.52
15 Apr 20203.91%6.38
30 Apr 20203.26%7.12
15 May 20204.10%10.6310-Q filed
29 May 20203.55%10.70
15 Jun 20203.82%11.28
30 Jun 20203.98%5.70
15 Jul 20204.35%13.27
31 Jul 20204.44%14.74
14 Aug 20204.35%13.9610-Q filed, results (8-K)
31 Aug 20204.31%5.97
15 Sep 20204.68%4.84
30 Sep 20204.56%7.40
15 Oct 20204.61%9.22
30 Oct 20204.04%10.41
13 Nov 20204.31%10.1710-Q filed, results (8-K)
30 Nov 20204.68%5.60
15 Dec 20204.00%4.18
31 Dec 20206.24%6.28

See also: RHYTHM PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.